The estimated Net Worth of Christopher Downs is at least $411 Thousand dollars as of 1 February 2024. Mr Downs owns over 66,666 units of Cns Pharmaceuticals Inc stock worth over $16,550 and over the last 8 years he sold CNSP stock worth over $0. In addition, he makes $394,700 as Chief Financial Officer at Cns Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr A CNSP stock SEC Form 4 insiders trading
Mr has made over 8 trades of the Cns Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 66,666 units of CNSP stock worth $20,000 on 1 February 2024.
The largest trade he's ever made was buying 142,000 units of Cns Pharmaceuticals Inc stock on 24 August 2020 worth over $289,680. On average, Mr trades about 15,099 units every 139 days since 2016. As of 1 February 2024 he still owns at least 103,438 units of Cns Pharmaceuticals Inc stock.
You can see the complete history of Mr Downs stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Christopher S. Downs CPA, CTP, FP&A biography
Christopher S. Downs CPA, CTP, FP&A is the Chief Financial Officer at Cns Pharmaceuticals Inc.
What is the salary of Mr A?
As the Chief Financial Officer of Cns Pharmaceuticals Inc, the total compensation of Mr A at Cns Pharmaceuticals Inc is $394,700. There are 1 executives at Cns Pharmaceuticals Inc getting paid more, with John Michael Climaco Esq., J.D. having the highest compensation of $635,100.
How old is Mr A?
Mr A is 42, he's been the Chief Financial Officer of Cns Pharmaceuticals Inc since . There are 3 older and no younger executives at Cns Pharmaceuticals Inc. The oldest executive at Cns Pharmaceuticals Inc is Dr. Donald H. Picker Ph.D., 75, who is the Chief Science Officer.
Insiders trading at Cns Pharmaceuticals Inc
Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over $132,960 worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth $458,622 . The most active insiders traders include Christopher Downs, John M Climaco, and Waldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of $6,051. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth $10,000.
What does Cns Pharmaceuticals Inc do?
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
What does Cns Pharmaceuticals Inc's logo look like?
Complete history of Mr Downs stock trades at InfuSystem Inc and Cns Pharmaceuticals Inc
Cns Pharmaceuticals Inc executives and stock owners
Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
John Michael Climaco Esq., J.D.,
Chairman, CEO & Pres -
Christopher S. Downs CPA, CTP, FP&A,
Chief Financial Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer -
Dr. Donald H. Picker Ph.D.,
Chief Science Officer -
Dr. Waldemar Priebe Ph.D.,
Founder & Chairman of the Scientific Advisory Board -
Amy Mahery,
Director -
Biosciences, Inc. Cortice,
-
Christopher Downs,
Chief Financial Officer -
Jerzy Gumulka,
Director -
Carl Anthony Evans,
Director -
Jeffry R. Keyes,
Director -
John M Climaco,
Chief Executive Officer -
Waldemar Priebe,
-
Faith L. Charles,
Director -
Bettina M. Cockroft,
Director